A novel membrane-based anti-diabetic action of atorvastatin

Emily M. Horvath, Lixuan Tackett, Jeffrey Elmendorf

Research output: Contribution to journalArticle

12 Citations (Scopus)

Abstract

We recently found that chromium picolinate (CrPic), a nutritional supplement thought to improve insulin sensitivity in individuals with impaired glucose tolerance, enhances insulin action by lowering plasma membrane (PM) cholesterol. Recent in vivo studies suggest that cholesterol-lowering statin drugs benefit insulin sensitivity in insulin-resistant patients, yet a mechanism is unknown. We report here that atorvastatin (ATV) diminished PM cholesterol by 22% (P < 0.05) in 3T3-L1 adipocytes. As documented for CrPic, this small reduction in PM cholesterol enhanced insulin action. Replenishment of cholesterol mitigated the positive effects of ATV on insulin sensitivity. Co-treatment with CrPic and ATV did not amplify the extent of PM cholesterol loss or insulin sensitivity gain. In addition, analyses of insulin signal transduction suggest a non-signaling basis of both therapies. Our data reveal an unappreciated beneficial non-hepatic effect of statin action and highlight a novel mechanistic similarity between two recently recognized therapies of impaired glucose tolerance.

Original languageEnglish
Pages (from-to)639-643
Number of pages5
JournalBiochemical and Biophysical Research Communications
Volume372
Issue number4
DOIs
StatePublished - Aug 8 2008

Fingerprint

Cholesterol
Insulin
Membranes
Insulin Resistance
Cell membranes
Cell Membrane
Hydroxymethylglutaryl-CoA Reductase Inhibitors
Glucose Intolerance
Adipocytes
Glucose
Signal transduction
Atorvastatin Calcium
Signal Transduction
Therapeutics
Pharmaceutical Preparations
picolinic acid

Keywords

  • Atorvastatin
  • Cholesterol
  • GLUT4
  • Insulin
  • Insulin resistance
  • Plasma membrane

ASJC Scopus subject areas

  • Biochemistry
  • Biophysics
  • Molecular Biology

Cite this

A novel membrane-based anti-diabetic action of atorvastatin. / Horvath, Emily M.; Tackett, Lixuan; Elmendorf, Jeffrey.

In: Biochemical and Biophysical Research Communications, Vol. 372, No. 4, 08.08.2008, p. 639-643.

Research output: Contribution to journalArticle

@article{05acd7bd0f214dcfa21330dd6aa6e981,
title = "A novel membrane-based anti-diabetic action of atorvastatin",
abstract = "We recently found that chromium picolinate (CrPic), a nutritional supplement thought to improve insulin sensitivity in individuals with impaired glucose tolerance, enhances insulin action by lowering plasma membrane (PM) cholesterol. Recent in vivo studies suggest that cholesterol-lowering statin drugs benefit insulin sensitivity in insulin-resistant patients, yet a mechanism is unknown. We report here that atorvastatin (ATV) diminished PM cholesterol by 22{\%} (P < 0.05) in 3T3-L1 adipocytes. As documented for CrPic, this small reduction in PM cholesterol enhanced insulin action. Replenishment of cholesterol mitigated the positive effects of ATV on insulin sensitivity. Co-treatment with CrPic and ATV did not amplify the extent of PM cholesterol loss or insulin sensitivity gain. In addition, analyses of insulin signal transduction suggest a non-signaling basis of both therapies. Our data reveal an unappreciated beneficial non-hepatic effect of statin action and highlight a novel mechanistic similarity between two recently recognized therapies of impaired glucose tolerance.",
keywords = "Atorvastatin, Cholesterol, GLUT4, Insulin, Insulin resistance, Plasma membrane",
author = "Horvath, {Emily M.} and Lixuan Tackett and Jeffrey Elmendorf",
year = "2008",
month = "8",
day = "8",
doi = "10.1016/j.bbrc.2008.05.095",
language = "English",
volume = "372",
pages = "639--643",
journal = "Biochemical and Biophysical Research Communications",
issn = "0006-291X",
publisher = "Academic Press Inc.",
number = "4",

}

TY - JOUR

T1 - A novel membrane-based anti-diabetic action of atorvastatin

AU - Horvath, Emily M.

AU - Tackett, Lixuan

AU - Elmendorf, Jeffrey

PY - 2008/8/8

Y1 - 2008/8/8

N2 - We recently found that chromium picolinate (CrPic), a nutritional supplement thought to improve insulin sensitivity in individuals with impaired glucose tolerance, enhances insulin action by lowering plasma membrane (PM) cholesterol. Recent in vivo studies suggest that cholesterol-lowering statin drugs benefit insulin sensitivity in insulin-resistant patients, yet a mechanism is unknown. We report here that atorvastatin (ATV) diminished PM cholesterol by 22% (P < 0.05) in 3T3-L1 adipocytes. As documented for CrPic, this small reduction in PM cholesterol enhanced insulin action. Replenishment of cholesterol mitigated the positive effects of ATV on insulin sensitivity. Co-treatment with CrPic and ATV did not amplify the extent of PM cholesterol loss or insulin sensitivity gain. In addition, analyses of insulin signal transduction suggest a non-signaling basis of both therapies. Our data reveal an unappreciated beneficial non-hepatic effect of statin action and highlight a novel mechanistic similarity between two recently recognized therapies of impaired glucose tolerance.

AB - We recently found that chromium picolinate (CrPic), a nutritional supplement thought to improve insulin sensitivity in individuals with impaired glucose tolerance, enhances insulin action by lowering plasma membrane (PM) cholesterol. Recent in vivo studies suggest that cholesterol-lowering statin drugs benefit insulin sensitivity in insulin-resistant patients, yet a mechanism is unknown. We report here that atorvastatin (ATV) diminished PM cholesterol by 22% (P < 0.05) in 3T3-L1 adipocytes. As documented for CrPic, this small reduction in PM cholesterol enhanced insulin action. Replenishment of cholesterol mitigated the positive effects of ATV on insulin sensitivity. Co-treatment with CrPic and ATV did not amplify the extent of PM cholesterol loss or insulin sensitivity gain. In addition, analyses of insulin signal transduction suggest a non-signaling basis of both therapies. Our data reveal an unappreciated beneficial non-hepatic effect of statin action and highlight a novel mechanistic similarity between two recently recognized therapies of impaired glucose tolerance.

KW - Atorvastatin

KW - Cholesterol

KW - GLUT4

KW - Insulin

KW - Insulin resistance

KW - Plasma membrane

UR - http://www.scopus.com/inward/record.url?scp=45449087250&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=45449087250&partnerID=8YFLogxK

U2 - 10.1016/j.bbrc.2008.05.095

DO - 10.1016/j.bbrc.2008.05.095

M3 - Article

C2 - 18514061

AN - SCOPUS:45449087250

VL - 372

SP - 639

EP - 643

JO - Biochemical and Biophysical Research Communications

JF - Biochemical and Biophysical Research Communications

SN - 0006-291X

IS - 4

ER -